Received Sep 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 1 | 946908 | IM / LA |
Pt presented to clinic with facial hives, while conducting pt assessment, pt began to develop further hives on sternum. No c/o shortness of breath or other secondary effects related to allergic reaction.
None per pt.
DM Type 2, Hepatic Fibrosis, Fatty liver, Atrophy of Kidney
Unknown, per pt no medications.
NKA.
No